A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.
暂无分享，去创建一个
Myung Ah Lee | P. Philip | A. Hezel | N. Dhani | G. Vlahović | D. Oh | G. Fisher | E. O’Reilly | D. Renouf | Weijing Sun | Shao-chun Chang | Yin Yang | O. Takahashi